RecruitingNCT02819882
A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)
Sponsor
Spanish Breast Cancer Research Group
Enrollment
1,867 participants
Start Date
Aug 1, 2016
Study Type
OBSERVATIONAL
Conditions
Summary
This study is a prospective, multicenter non-interventional cohort study designed to develop a registry in unresectable locally advanced or metastatic disease.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Patients (males or females) diagnosed with unresectable locally advanced or MBC (either after a recurrence or as first diagnosis) from January 2016 onwards.
- Patients who died are allowed to be included on the study.
- Able and willing to provide written informed consent if they are alive.
- Age ≥ 18 years.
- Availability to medical records access and all data related to the disease management.
Exclusion Criteria1
- None
Interventions
OTHERNo intervention
Locations(40)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02819882
Related Trials
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892139 locations
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807149 locations
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
NCT0679763517 locations
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700234 locations
Longitudinal Body Composition Assessment in Breast Cancer Patients
NCT074728031 location